Journal Watch

« Back to Most Recent

  • PD Glucose Absorption and Lipid Profiles

    Lipid status was assessed at baseline and 12 month in 143 CAPD patients, 2/3 of whom used a daytime icodextrin exchange. No associations were found between glucose absorption, lipid profiles, or changes in serum lipids.

    Read the abstract » | (added 2020-02-19)

    Tags: Peritoneal Dialysis, Cholesterol, Glucose, Triglycerides

  • Icodextrin Reduces PD Stroke Risk

    Stroke risk was compared in PD patients in Taiwan who did or did not use icodextrin. Icodextrin users had a lower risk and incidence of strokes than non-users.

    Read the abstract » | (added 2018-12-14)

    Tags: Stroke, PD Patients, Icodexytrin

  • Starting PD with One Daily Exchange of Icodextrin

    Incremental PD can be less restrictive for patients initiating therapy. Is one daily exchange with icodextrin enough? A physiological study used a 3-pore kinetic model to assess fluid and solute removal among patients with residual function that ranged from 0 to 15 mL/min/1.73m2. All but very large patients (total body water >60L) were predicted to achieve adequate dialysis with this approach.

    Read the abstract » | (added 2018-02-15)

    Tags: Incremental PD, Icodextrin, Fluid And Solute Removal

  • New PD Strategies Using Icodextrin

    A new article reports that icodextrin can be used in new ways, such as twice-daily exchanges and a single nocturnal PD exchange for treatment of congestive heart failure.

    Read the abstract » | (added 2017-07-14)

    Tags: Education Issues: For Patients And Professionals

  • Kinetic modeling helps predict best PD prescription

    Researchers found 12 subgroups among 1,005 people on PD, based on their membrane transport and amount of body water. Using PD Adequest 2.0, patients each had a PD prescription tailored to reach a minimum adequacy target for urea and water, using glucose and icodextrin fluids. A cut-off of more or less than 2mL/min of residual kidney function was identified. Use of icodextrin simplified the regimen and reduced glucose exposure and PD fluid volumes.

    Read the abstract » | (added 2015-09-11)


  • Icodextrin PD fluid reduces insulin resistance in non-diabetic patients

    Even without diabetes, insulin resistance can add to cardiovascular disease risk in people with CKD. A new study randomized non-diabetic adults to APD with 2.5% glucose (n=27) for the long dwell or icodextrin 7.5% (n=33). At 90 days, the icodextrin group had lower levels of insulin resistance.

    Read the abstract » | (added 2015-07-08)


  • Icodextrin reduces PD failure and boosts survival

    In a prospective trial of 306 incident PD patients between 2007 and 2011, those who used icodextrin were significantly more likely to continue with PD and more likely to live longer than those who used standard PD fluid.

    Read the abstract » | (added 2015-04-10)


  • Don’t trust glucometers on people using PD with icodextrin

    Glucometer test strips can’t distinguish glucose from other sugars, like maltose. When icodextrin is used for PD in people with diabetes, standard glucometer use is risky. Blood glucose test results from glucometers can’t be trusted, and people may be given insulin they don’t need (which could cause coma or death). Three case reports show why this is the case—and the authors suggest using glucose-specific blood tests instead.

    Read the abstract » | (added 2014-12-09)


  • All about icodextrin – in one place

    A new review explains why and how to use icodextrin appropriately and avoid adverse events. Learn about the hemodynamic, metabolic, and idiopathic effects of this glucose-sparing PD fluid so you can prescribe it with confidence.

    Read the abstract » | (added 2014-07-07)


  • Japanese strategy to prevent encapsulating peritoneal sclerosis (EPS)

    EPS is a rare and severe complication of PD. Japanese clinicians offer a multidisciplinary approach to avoid EPS and improve outcomes for those who have it. Icodextrin and combination PD/HD treatment is used, and high-risk patients have planned PD stoppage. Between 2008 and 2012, the incidence of EPS was 0.3% for PD < 3 years, 0.6% for PD = 5 years, 2.3% for PD = 8 years, and 1.2% for PD > 8 years. Prednisone (n=11) and surgery (n=2) were used to treat EPS; remission occurred in 12 of the patients (85.7%), while 3 died (21.4%).

    Read the abstract » | (added 2014-03-07)